Form 4 for PHIO Phio Pharmaceuticals Corp.
Accepted 2022-11-16 00:00:00 ET · period of report 2022-11-16 · accession 0001209191-22-057333 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-11-16 | 2022-11-16 | PHIO | Bitterman Robert J | Interim Executive COB, Dir | P - Purchase | $1,750.00 | +1 | 1 | New | +$1,750 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Series D Preferred Stock, $0.0001 par value | 2022-11-16 | P | A | 1 | $1,750.00 | 1 | D | — | — | (F1) The outstanding share of Series D Preferred Stock shall be redeemed in whole, but not in part, at any time: (i) if such redemption is approved by the Board of Directors in its sole discretion or (ii) automatically and effective upon the approval of an amendment to the Certificate of Incorporation to implement a reverse stock split. Upon redemption, the share of Series D Preferred Stock will receive consideration of $1,750.00 in cash. |